Post PCI bleeding can cause kidney injury

Original title: Impact of Periprocedural Bleeding on Incidente of Constrast-Induced Acute Kidney Injury in patients treated with Percutaneous Coronary Intervention. Reference: Yohei Ohno, et al. J Am Coll Cardiol 2013;62:1260-6

Contrast induced acute kidney injury (CI-AKI) is a serious complication associated to higher morbimortality rates and higher costs, but its correlation to bleeding remains controversial. This study included 2646 patients undergoing PCI; 315 (12%) presented CI AKI. 

Patients were divided in 5 groups according to hemoglobin variation after PCI (Hb): Group A showed no change in Hb levels (290 patients), B: a decrease in Hb 3 g/dl (244 patients). There were no differences in baseline characteristics between the groups.

Kidney injury was associated to cardiac insufficiency CF III or IV, infarction with ST segment elevation, as well as a greater decrease in HB levels (odds ratio 2.23, IC 95% 1.37 to 3.63 p=0.001). CI-AKI patients presented higher rates of mortality compared to stable patients, as well as a composite of heart failure, cardiogenic shock, death, major bleeding and need of transfusion.

There was a significative correlation between HB level decrease and the events rate that, globally, resulted in 12%. Each group separately showed different rates:  A 6%, B 8%, C 11%, D 17% y E 26% (p<0.001). Minor bleeding did not have significant impact.

Conclusion:

Periprocedural bleeding was significantly associated with CI-AKI, with CI-AKI incidence correlating with bleeding severity. These patients presented high risk of in-hospital mortality.

Comment:

It is known that kidney injury is a marker of bad evolution. This analysis also shows that bleeding may cause kidney injury after PCI and, in addition, it marks a bad evolution. It is important to remember the transradial approach reduces major bleeding events and, hence, should be the first choice not only for PC interventions but also for catheterizations.

Courtesy of Dr Carlos Fava,
Interventional cardiologist
Favaloro Foundation
Buenos Aires – Argentina 

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Left Main Coronary Artery Disease: Intravascular Imaging-Guided PCI vs. Coronary Artery Bypass Grafting

Multiple randomized clinical trials have demonstrated superior outcomes with coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) in patients with left main...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...